2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 32

Comparison of Effects of Leukocyte-RICH and Leukocyte-Poor Platelet-RICH Plasma on PAIN and Functionality in Patients with Lateral Epicondylitis
Abstract Number: 1220

Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative
Abstract Number: 726

Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice
Abstract Number: 2586

Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial
Abstract Number: 2538

Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis
Abstract Number: 2815

Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Abstract Number: 559

Comparison of Multi-Dimensional Health Assessment Questionnaire (MD-HAQ)-Based and Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Based Routine Assessment of Patient Index 3 (RAPID3) for Assessing Rheumatoid Arthritis Disease Activity
Abstract Number: 2202

Comparison of New and Old American College of Rheumatology Classification Criterion for Diagnosis of Fibromyalgia
Abstract Number: 482

Comparison of Nonclinical Pharmacology, Pharmacodynamics and Efficacy Response of the Proposed Adalimumab Biosimilar GP2017 to Originator Adalimumab
Abstract Number: 2197

Comparison of Objectively Measured Physical Activity Among People with Symptomatic Knee Osteoarthritis with the General US Population
Abstract Number: 1371

Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis
Abstract Number: 2953

Comparison of Patient Outcomes in Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome
Abstract Number: 1245

Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective
Abstract Number: 2356

Comparison of Spa Therapy with or without Physical Rehabilitation for Knee Osteoarthritis: A Randomized Controlled Trial
Abstract Number: 16L

Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].